First identification of blaIMI-1 in an Enterobacter cloacae clinical isolate from France.
Thierry
T
Naas
Christian
C
Cattoen
Stéphanie
S
Bernusset
Gaelle
G
Cuzon
Patrice
P
Nordmann
D000328:Adult; D000583:Amikacin / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015780:Carbapenems / Q000494:pharmacology / Q000627:therapeutic use; D016972:Enterobacter cloacae / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D004756:Enterobacteriaceae Infections / Q000188:drug therapy / Q000382:microbiology; D005602:France; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D010878:Piperacillin / Q000494:pharmacology / Q000627:therapeutic use; D053717:Pneumonia, Ventilator-Associated / Q000188:drug therapy / Q000382:microbiology; D012336:RNA, Ribosomal, 16S / Q000235:genetics*; D017422:Sequence Analysis, DNA; D000078142:Tazobactam; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000235:genetics* / Q000378:metabolism
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D012336:RNA, Ribosomal, 16S; D000583:Amikacin; D010397:Penicillanic Acid; D001618:beta-Lactamases; D000078142:Tazobactam; D010878:Piperacillin